Tyra Biosciences/$TYRA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Tyra Biosciences
Tyra Biosciences Inc is a clinical-stage biotechnology company focused on developing next-generation precision medicines for large opportunities in targeted oncology and genetically defined conditions, harnessing the power of Fibroblast Growth Factor Receptor (FGFR) biology. The company's in-house precision medicine platform, SNAP, enables rapid and precise drug design through iterative molecular SNAPshots that help to design and predict which product candidates may demonstrate the highest potency, selectivity, and tolerability in the clinic. The various drug candidates in the company's product pipeline are FGFR3, FGFR4/3, and FGFR1/2/3: three clinical-stage, novel small molecules designed to overcome the toxicity and resistance liabilities of first-generation pan-FGFR inhibitors.
- Ticker
- $TYRA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 87
- Headquarters
- Carlsbad, United States
- Website
- tyra.bio
Tyra Biosciences Metrics
BasicAdvanced
$1.5bn
-
-$2.40
0.77
-
Price and volume
Market cap
$1.5bn
Beta
0.77
52-week high
$40.65
52-week low
$9.96
Average daily volume
652k
Financial strength
Current ratio
14.905
Quick ratio
14.478
Long term debt to equity
1.436
Total debt to equity
1.578
Profitability
EBITDA (TTM)
-159.922
Management effectiveness
Return on assets (TTM)
-28.46%
Return on equity (TTM)
-45.31%
Valuation
Price to book
4.27
Price to tangible book (TTM)
4.27
Price to free cash flow (TTM)
-14.232
Free cash flow yield (TTM)
-7.03%
Free cash flow per share (TTM)
-1.778
Growth
Earnings per share change (TTM)
34.46%
3-year earnings per share growth (CAGR)
26.21%
What the Analysts think about Tyra Biosciences
Analyst ratings (Buy, Hold, Sell) for Tyra Biosciences stock.
Tyra Biosciences Financial Performance
Revenues and expenses
Tyra Biosciences Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.